AI Summary
Dr. Griffin provides a clinical update discussing the impact of the pandemic on trust in healthcare professionals, strain selection for influenza vaccines, statistics on SARS-CoV-2 infection, the effects of COVID-19 vaccines on the cardiovascular system, the effectiveness of a third dose of mRNA vaccine, and long-term consequences of a SARS-CoV-2 infection such as diabetes, respiratory problems, hearing loss, and maternal-fetal health. The update covers various resources, guidelines, and studies related to COVID-19 treatment and management.
In his weekly clinical update, Dr. Griffin discusses how the pandemic may have affected our trust in physicians and hospitals and if waiting longer to make strain selection for the seasonal influenza vaccine would be advantageous before reviewing the recent statistics on SARS-CoV-2 infection, how different CVODI-19 vaccines effect the cardiovascular system, if the a third of either COVID-19 mRNA vaccine is effective, where to find PEMGARDA, if convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, and the long term consequences of a SARS-CoV-2 infection on human health including incidences of diabetes, respiratory problems, hearing loss and maternal-fetal health.
Click arrow to play
Download TWiV 1136 (31 MB .mp3, 43 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- In physicians and hospitals, we trust (JAMA Network)
- Are there benefits for delaying seasonal influenza vaccine selections (JID)
- Personal protective effect for wearing surgical face masks in public spaces (the BMJ)
- COVID-19 national trend (CDC)
- COVID-19 deaths (CDC)
- Cardiovascular safety of different COVID-19 vaccination(Nature Comm)
- Effectiveness of a third dose of mRNA-1273 versus BNT162b2 among older adults (Vaccine)
- Where to get pemgarda (Pemgarda)
- CDC Quarantine guidelines (CDC)
- Early phase of SARs-CoV-2 infection (COVID.gov)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Drug interaction checker (University of Liverpool)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- Managing healthcare staffing shortages (CDC)
- Steroids,dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Incidence of diabetes after SARS-CoV-2 infection (The Lancet Diabetes & Endocrinology)
- Post-COVID-19 respiratory sequelae two years after hospitalization (The Lancet Regional Health)
- Incidence of hearing loss following COVID-19 among young adults (eClinical Medicine)
- The effect of long-term COVID-19 infection on maternal and fetal complications (Scientific Reports)
- Contribute to our Floating Doctors fundraiser
- Letters read on TWiV 1136
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
The post TWiV 1136: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.